Researchers exploring alternatives to statins for inhibiting the cholesterol synthetic pathway thus turned to CYP51A1 as a potential anticancer target, and antifungal CYP51A1 inhibitor drugs are being tested for anticancer efficacy.

GVK BIO was commissioned to enable one such project where the client was exploring the possibility of re-purposing an internal collection of antifungal CYP51A1 inhibitors for targeting cancers.

Download our whitepaper to understand how this project went on to yield high potency compounds for the client which allowed them to further their drug discovery plans.

A Novel Cell-based Screening Assay for Cholesterol Biosynthetic
Pathway Inhibition Using the RapidFire HTMS Platform

© 2019 GVK Biosciences Private Limited. All Rights Reserved
Terms & Conditions | Privacy Policy | Privacy Notice - Customers/Vendors/Job Applicants

Please complete the form to download